Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Faries, Douglas
Ascher-Svanum, Haya
and
Belger, Mark
2007.
Analysis of Treatment Effectiveness in Longitudinal Observational Data.
Journal of Biopharmaceutical Statistics,
Vol. 17,
Issue. 5,
p.
809.
Knapp, Martin
Windmeijer, Frank
Brown, Jacqueline
Kontodimas, Stathis
Tzivelekis, Spyridon
Haro, Josep Maria
Ratcliffe, Mark
Hong, Jihyung
and
Novick, Diego
2008.
Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study.
PharmacoEconomics,
Vol. 26,
Issue. 4,
p.
341.
Salize, Hans Joachim
McCabe, Rosemarie
Bullenkamp, Jens
Hansson, Lars
Lauber, Christoph
Martinez-Leal, Rafael
Reinhard, Iris
Rössler, Wulf
Svensson, Bengt
Torres-Gonzalez, Francisco
van den Brink, Rob
Wiersma, Durk
and
Priebe, Stefan
2009.
Cost of treatment of schizophrenia in six European countries.
Schizophrenia Research,
Vol. 111,
Issue. 1-3,
p.
70.
Furiak, Nicolas M
Ascher-Svanum, Haya
Klein, Robert W
Smolen, Lee J
Lawson, Anthony H
Conley, Robert R
and
Culler, Steven D
2009.
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.
Cost Effectiveness and Resource Allocation,
Vol. 7,
Issue. 1,
De Ridder, Annemieke
and
De Graeve, Diana
2009.
Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach.
PharmacoEconomics,
Vol. 27,
Issue. 1,
p.
69.
Alonso, Jordi
Croudace, Tim
Brown, Jacqueline
Gasquet, Isabelle
Knapp, Martin R.J.
Suárez, David
and
Novick, Diego
2009.
Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment: 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study.
Value in Health,
Vol. 12,
Issue. 4,
p.
536.
Stollenwerk, Björn
Stock, Stephanie
Siebert, Uwe
Lauterbach, Karl W.
and
Holle, Rolf
2010.
Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss’s Error Propagation, an Alternative to Established Methods.
Medical Decision Making,
Vol. 30,
Issue. 3,
p.
304.
De Ridder, Annemieke
and
De Graeve, Diana
2011.
Can we account for selection bias? A comparison between bare metal and drug-eluting stents.
Value in Health,
Vol. 14,
Issue. 1,
p.
3.
Canavan, Caroline
West, Joe
and
Card, Timothy
2016.
Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment.
PharmacoEconomics,
Vol. 34,
Issue. 2,
p.
181.
Silarova, Barbora
Nelis, Sharon M.
Ashworth, Rosalie M.
Ballard, Clive
Bieńkiewicz, Marta
Henderson, Catherine
Hillman, Alexandra
Hindle, John V.
Hughes, Julian C.
Lamont, Ruth A.
Litherland, Rachael
Jones, Ian R.
Jones, Roy W.
Knapp, Martin
Kotting, Piers
Martyr, Anthony
Matthews, Fiona E.
Morris, Robin G.
Quinn, Catherine
Regan, Jemma
Rusted, Jennifer M.
van den Heuvel, Eleanor Ann
Victor, Christina R.
Wu, Yu-Tzu
and
Clare, Linda
2018.
Protocol for the IDEAL-2 longitudinal study: following the experiences of people with dementia and their primary carers to understand what contributes to living well with dementia and enhances active life.
BMC Public Health,
Vol. 18,
Issue. 1,